光动力疗法治疗中心性渗出性脉络膜视网膜病变疗效观察

目的 评价光动力疗法(photodynamictherapy,PDT)治疗中心性渗出性脉络膜视网膜病变(centralexudativehorioretinopathy,CEC)的临床疗效.方法 对比分析中心性渗出性脉络膜视网膜病变所致黄斑部脉络膜新生血管(choroidaineovascularization,CNV)患眼21例,治疗前与单次PDT治疗后3个月的视力、眼底、固视性质、光学相干断层扫描(optic coherence tomograph,OCT)图像及荧光素钠血管造影(fundus fluoresein angiography,FFA)、吲哚菁绿血管造影(indocyanine greenan giography,ICGA)的变化.结果 PDT治疗后3个月11只眼视力提高(52.38%),10只眼视力稳定(47.62%),其中5例由偏心固视恢复为中心固视.眼底检查可见出血渗出明显减少,部分患者完全吸收.FFA联合ICGA检查显示CNV病灶渗漏停止10只眼(47.62%),渗漏减少10只眼(47.62%);OCT检查表现为CNV缩小.组织水肿减轻.结论 PDT治疗可以部分或完全封闭中心性渗出性脉络膜视网膜病变所致的CNV,减少CNV引起的视力下降的危险性.     

光动力疗法治疗渗出性年龄相关性黄斑变性

目的观察光动力疗法(photodynamic therapy,PDT)治疗渗出性年龄相关性黄斑变性(age-related macular degeneration,AMD)的疗效。方法回顾分析经荧光素眼底血管造影(fundus fluorescein angiography,FFA)、吲哚菁绿血管造影(indocyanine green angiography,ICGA)以及光学相干断层扫描(optical coherence tomography,OCT)检查确诊的21例(31眼)渗出性AMD患者PDT治疗前及治疗后的临床资料,主要以视力、FFA及(或)ICGA、OCT的改变为观察指标,评价PDT对渗出性AMD的治疗效果。结果治疗后13眼视力明显改善(视力提高≥2行),占41.9%;14眼视力稳定不变(视力波动在1行以内),占45.2%;4眼视力下降2行,占12.9%。大部分患眼于PDT治疗后眼底出血和渗出减轻;ICGA检查显示:PDT治疗后1周,16眼CNV的渗漏明显减少或完全停止,8眼渗漏完全停止。OCT检查显示:CNV周围视网膜脉络膜水肿以及神经上皮脱离好转。5例6眼患者在PDT治疗过程中及治疗后发生视网膜神经上皮脱离范围变大,1例1眼发生黄斑部再次大面积出血,所有病例均未发生任何全身不良反应。结论单次和重复PDT治疗可以部分或完全封闭渗出性AMD的CNV,PDT治疗对病灶周围的正常视网膜和脉络膜组织短期内有轻度影响,对视力无损害。     

光动力疗法治疗老年性黄斑变性合并脉络膜新生血管的临床观察

目的 观察单次光动力疗法(photodynamic therapy, PDT)治疗渗出型老年性黄斑变性(age-related macular degeneration, AMD)合并脉络膜新生血管(choroidal neovascularization, CNV)的短期治疗效果。 方法 回顾分析经荧光素眼底血管造影(fundus fluorescein angiography, FFA)、吲哚青绿血管造影(indocyanine green angiography,ICGA)和光相干断层成像术(optic coherence tomography, OCT)等检查确诊的30例渗出型AMD患者的35只患眼行PDT治疗前和治疗后1周,1、3个月的临床资料，以视力、FFA、ICGA和OCT检查结果为观察指标，评价PDT对渗出型AMD的短期治疗效果。 结果 治疗后3 个月内有34只眼视力不变或提高，1只眼因出血而视力下降；FFA检查显示有19只眼荧光素渗漏减轻或完全消退；OCT检查显示视网膜水肿和浆液性脱离明显好转。全部患者治疗过程中未发生任何不良反应；治疗后3例患者主诉有一过性视物变暗，2例主诉轻微背痛。 结论 PDT治疗渗出型AMD时，可短期封闭CNV，使渗漏减轻或消退，对视力无损害。 (中华眼底病杂志, 2002, 18: 171-174)     

中心性渗出性脉络膜视网膜病变的吲哚青绿造影特征

目的:分析中心性渗出性脉络膜视网膜病变(central exudative chorioretinopathy,CEC)吲哚青绿血管造影(indocyaninegreen angiography,ICGA)特点。方法:应用海德堡造影系统HRA2对24例24眼CEC患者进行荧光素、吲哚青绿眼底血管造影,并对ICGA与眼底荧光造影(fundus fluorescein angiography,FFA)结果进行对比分析。结果:CEC患者24眼FFA均证实为典型性脉络膜新生血管(choroidal neovascularization,CNV)。ICGA早期,24例CEC可见边界清晰的网状CNV。5例见CNV周围局限性脉络膜血管扩张。ICGA晚期可见CNV处染料渗漏或染色。20眼ICGA早期可见宽窄不一的暗环包绕CNV,4眼未见暗环。ICGA晚期,24眼CNV周围均可见暗环。1例患者光动力(photodynamic therapy,PDT)治疗后2mo,因视力继续下降复查ICGA,可见视网膜脉络膜血管吻合(retinal-choroidal anastomosis,RCA)。结论:由HRA2进行的ICGA对CEC的CNV的结构、边界、局部脉络膜静脉的改变、RCA的显示优于FFA。     

光动力疗法治疗病理性近视脉络膜新生血管的临床观察

目的 探讨光动力疗法(PDT)治疗病理性近视(PM)黄斑部脉络膜新生血管(cNV)短期的安全性和有效性.方法 回顾经临床眼底检查、FFA和/或ICGA检查及确诊的继发于PM的CNV患者19例(19只眼)行PDT治疗前后的临床资料,对比分析其最佳矫正视力、眼底像、眼底血管造影CNV渗漏、OCT及mf-ERG检查结果.光动力治疗方案参照TAP制定的标准.随访时间为3-6个月.结果 PDT治疗后全部患者视力改善或保持不变,无视力下降者.所有患眼底出血或渗出均减轻.FFA/ICGA检查显示:CNV停止渗漏11只眼,占57.89%;渗漏减少8只,占42.11%.OCT检查显示CNV明显变薄.PDT治疗后1个月mf-ERG3-5环N1、P1波波振幅密度值与治疗前均有显著提高(P＜0.05),3个月时3～4环N1、P1波振幅密度值与治疗前均有显著提高(P＜0.05).结论 病理性近视CNV经PDT治疗短期有效,安全性好,PDT治疗CNV的长期疗效有待进一步观察.     

光动力疗法治疗中心凹下脉络膜新生血管疗效观察

目的 观察光动力疗法(PDT)治疗中心凹下脉络膜新生血管(CNV)的临床疗效及安全性.方法 回顾分析经荧光素眼底血管造影(FFA),个别行吲哚氰绿血管造影(ICGA)和相干光断层成像术(OCT)等检查,确诊为中心凹下CNV29例(30只眼)进行Plyr治疗.对其治疗前后的视力、FFA、OCT检查结果进行对比分析,评价PDT对中心凹下CNV的治疗效果.结果 末诊视力提高10只眼占33%,稳定或不变者17只眼占57%,视力下降3只眼占10%.影像检查:FFA显示11只眼CNV无明显渗遍,OCT表现视网膜水肿吸收或减少,CNV反光团缩小并瘢痕化,16只眼渗遍减少,OCT检查强反射带变窄.3只眼渗遍增加,OCT检查视网膜色素上皮(RPE)-脉络膜毛细血管层强反光团扩大,神经上皮再次水肿增厚,伴有视网膜层间出血.30只眼其中28只眼进行1次治疗,2只眼进行了2次治疗.结论 PDT治疗中心凹下CNV对早期,病灶范围小的患者大多数是安全有效的.     

OCT对光动力疗法治疗CNV的疗效评估

目的：观察光学相干断层扫描(optical coherence tomography,OCT)评估光动力疗法(photodynamic therapy,PDT)治疗老年黄斑变性(age-related macular degeneration,AMD)、病理性近视(pathological myopia, PM)和中心性渗出性脉络膜视网膜病变(central exudative chorioretinopathy,CEC)引起的脉络膜新生血管(choroidal neovascularization,CNV)视网膜的疗效和安全性。

方法：回顾分析2010-01/2012-12经视力、眼压、荧光素眼底血管造影(fundus fluorescein angiography,FFA)、吲哚青绿血管造影(indocyanine green angiography,ICGA)和OCT检查,临床确诊为有CNV形成的临床患者资料,共53例53眼符合条件纳入观察。患者经PDT治疗后,每3mo进行随访复查,复发的患者再次进行PDT治疗。对比分析治疗前与治疗后1a患者最佳矫正视力(BCVA)及黄斑中心视网膜厚度(central macular thickness,CMT)的改变。

结果：截止随访结束时,患者经PDT治疗后,最佳矫正视力均比治疗前提高35例,视力稳定无明显变化15例,视力下降3例; 所有患者眼底渗漏均减轻,经FFA检查42例患者CNV闭合且渗漏完全停止,11例患者CNV大部分闭合。治疗前后患者视力及CMT改变均有统计学意义。整个治疗及随访中所有患者均未见与接受PDT治疗相关的眼部和全身不良反应。

结论：PDT治疗AMD患者CNV能够在1a内保持视力的稳定,且严重不良事件的发生率低,是AMD 患者CNV治疗的安全有效方法。     

病理性近视黄斑出血的眼底特征及光学相干断层扫描分析

目的:探讨病理性近视黄斑出血的眼底改变及其光学相干断层扫描特征。方法:对42例43眼病理性近视(PM)黄斑出血患者进行眼底彩色照相、荧光素眼底血管造影(FFA)和光学相干断层扫描(OCT)检查。结果:病理性近视黄斑出血的表现分为两类:新生血管型:24例24眼,其眼底特征表现为出血灶呈类圆形,不超过1PD,周围少见渗出及水肿,部分可见新生血管膜;其FFA特征表现为典型性CNV17眼(71%),隐匿性CNV7眼(29%);其OCT特征表现为21眼(87.5%)CNV呈纺锤形或类圆形团块状,呈强或中等强度反射,自视网膜色素上皮层向上突出,位于视网膜神经上皮层下,3眼(12.5%)CNV呈不规则增强紊乱的反射信号,位于视网膜色素上皮层平面。单纯型:18例19眼;其眼底特征表现为出血灶扁平,大小不等,边界欠整齐,周围无渗出及水肿,其FFA特征表现为出血遮蔽荧光,无CNV性高荧光征象,部分患眼可见漆裂纹样透见荧光;其OCT特征表现为色素上皮层下隆起低反射区,脉络膜毛细血管层光带连续。结论:病理性近视新生血管型黄斑出血绝大部分由典型性CNV引起,OCT的典型图像为色素上皮层局限的纺锤状或类圆形的强反射光团,边界较清,视网膜向上隆起,下方可有脉络膜遮蔽;单纯型黄斑出血表现为局限性色素上皮层出血性脱离,OCT检查有利于明确病理性近视黄斑出血的病变性质和病因,并有助于判断预后和指导治疗。     

光动力疗法联合玻璃体腔曲安奈德注射治疗脉络膜新生血管

目的观察光动力疗法(PDT)联合玻璃体腔曲安奈德(TA)注射治疗老年黄斑变性和病理性近视引起的脉络膜新生血管(CNV)的近期疗效和安全性。方法16例经过视力、眼压、荧光素眼底血管造影(FFA)以及光相干断层扫描(OCT)等检查确诊的CNV患者的16只患眼进行PDT联合玻璃体腔TA注射治疗。其中,渗出型老年黄斑变性14例14只眼,病理性近视2例2只眼。16只眼中,12只眼在PDT治疗后72 h行玻璃体腔TA注射,4只眼在PDT 3个月~1年(平均9个月)后行玻璃体腔TA注射。第1年的平均治疗次数为1.1次。联合治疗后,采用与治疗前相同的条件和检查方法进行随访观察,随访时间3~18个月,平均随访时间18.6个月。对比观察治疗前后患者的最佳矫正视力、眼压、CNV病灶渗漏情况以及黄斑区视网膜厚度变化。结果16只眼中,7只眼视力提高,占43.8%;9只眼视力稳定,占56.2%。FFA显示CNV病灶在联合治疗后渗漏停止或减轻,OCT显示黄斑区视网膜水肿消退或减轻。1只眼暂时性眼压升高,占6.3%。经药物短期治疗后恢复正常。结论PDT联合玻璃体腔TA注射可以安全有效地治疗CNV,延缓视力下降,并且可以减少重复治疗的次数。     

光动力疗法对病理性近视合并脉络膜新生血管患者的疗效观察

目的 观察光动力疗法（PDT）对病理性近视合并脉络膜新生血管（CNV）患者的疗效和安全性。方法回顾性分析2003年6月至2006年4月行PDT治疗的27例（32只眼）病理性近视合并CNV患者的临床资料,比较患者治疗前后视力、荧光素眼底血管造影（FFA）及相干光断层扫描（OCT）图像变化。结果27例患者的年龄为18～59岁,平均40岁;单眼CNV22例,双眼CNV5例;黄斑中心凹下CNV29只眼,旁中心凹CNV3只眼;近视度数为-6D～-12D,随访时间6个月至3年。末次随访时,视力提高两行以上者4只眼（12．5％）,保持稳定者27只眼（84．4％）,下降2行以上者1只眼（3．1％）;视物变形消失者29只眼（90．6％）。FFA检测显示伴有漆纹样裂纹者12只眼,CNV完全闭合者17只眼,部分闭合者9只眼,未闭合者6只眼。27例患者PDT治疗的平均次数为1．3次。结论PDT治疗病理性近视患者的CNV疗效满意,安全性较高,能显著降低中度和重度近视患者的视力下降,且症状明显减轻,可提高病理性近视患者的视觉生活质量。（中华跟科杂志,2007,43：638-641）     

Optical coherence tomography to monitor photodynamic therapy in pathological myopia

AIM: To evaluate the role of optical coherence tomography (OCT) in determining choroidal neovascularisation (CNV) activity before and after photodynamic therapy (PDT) in patients with pathological myopia. METHODS: 33 patients (33 eyes) with pathological myopia and being treated with PDT were included. Every 3 months all patients were evaluated and presence or absence of leakage on fluorescein angiography, presence of intraretinal or subretinal fluid on OCT, and macular and choroidal neovascular complex thickness on OCT, were determined at each examination. RESULTS: The macular thickness decreased significantly after PDT at 6 months (p = 0.001) and at 12 months follow up (p = 0.01). However, no significant changes in CNV thickness were measured after PDT at 6 months of follow up (p = 0.418) and at 12 months of follow up (p = 0.521). Once the diagnosis of CNV associated with pathological myopia was established, before treatment, OCT had a sensitivity of 96.96% for detecting CNV activity. After treatment, OCT had a good sensitivity (95.23%) and a moderate specificity (69,69%) in determining CNV activity, which resulted in a diagnostic efficiency (proportion of correct results) of 79.62%. CONCLUSIONS: OCT appears to be useful for indicating CNV activity. Therefore, it may serve as a complementary technique for deciding the need for PDT and re-treatment in patients with pathological myopia.     

特发性脉络膜新生血管采用光动力疗法后视网膜色素上皮损伤的研究

目的探讨特发性脉络膜新生血管（CNV）采用光动力疗法（PDT）后视网膜色素上皮（RPE）损伤的原因。方法对43例（45只眼）接受PDT治疗的特发性CNV患者资料进行回顾性分析,以25例（27只眼）CNV膜大小接近的病理性近视合并CNV患者作为对照。分析治疗后4周的荧光素眼底血管造影图像,判断病灶周围色素上皮的透见荧光情况,探讨治疗后8-12周CNV患者的复发原因。结果特发性CNV患者经初次治疗后,PDT光照区内有21只眼的RPE发生改变,二次治疗后又增加了1只眼,RPE改变的发生率约为48．9％,而病理性近视组仅2只眼经PDT治疗后RPE发生改变。随访期内4例特发性CNV患者经PDT治疗后CNV明显扩大。两组CNV患者男女比例基本相同,其男女RPE改变的发生率差异也无统计学意义（P〉0．05）。与病理性近视的CNV患者相比,特发性CNV患者的发病年龄较轻,而病理性近视的CNV患者经治疗后出现RPE改变的2例患者中,1例为37岁,1例为15岁。结论特发性CNV患者经PDT治疗后病灶周围出现RPE损伤,提示年轻患者易出现治疗后的过度反应。     

Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes

Context:

In India, refractive errors are a major cause of treatable blindness. Population surveys in southern India have shown prevalence of high myopia to be 4.32-4.54%. Photodynamic therapy (PDT) for choroidal neovascularization (CNV) caused by pathologic myopia is beneficial.

Aims:

To report the 24 months outcome of PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes

Settings and Design:

Prospective case series

Materials and Methods:

Review of prospectively collected data of Indian patients with pathologic myopia and subfoveal CNV treated with verteporfin therapy between 2001 and 2005 using standard regimen for PDT.

Statistical Analysis Used:

Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.

Results:

Fifteen patients (15 eyes) treated with standard fluence PDT and who had completed 24 months follow-up were analyzed. The mean spherical equivalent was -13.36 ± 5.88 diopter. Five out of 15 eyes in six months, three out of 15 eyes at 12 months and four eyes out of 15 at 24 months had improved vision by > 10 letters. The mean number of treatment session was 2.2 in two years.

Conclusions:

PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes is effective.     

Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia

Purpose To describe highly myopic patients in which either the large choroidal veins or arteries were occluded following PDT treatment.Methods Demographic features of two highly myopic patients in which large choroidal vessels were occluded at 1 week following PDT, among a total of 23 patients who received PDT due to choroidal neovascularization (CNV) caused by high myopia, were demonstrated.Results In case 1, ICG angiography demonstrated the complete occlusion of several large choroidal veins within the laser-applied area at 1 week after PDT. In case 2, ICG angiography demonstrated an occlusion of choroidal artery emanating from beneath the CNV. One month after PDT, re-perfusion of the occluded choroidal vessels was noted in both patients.Conclusion Occlusion of choroidal veins has never been reported in eyes with CNV treated by verteporfin therapy. Although further studies are necessary, occlusion of large choroidal vessels might happen in highly myopic eyes more commonly than expected. ICG angiography at 1 week after PDT was useful to evaluate the impact of PDT on large choroidal vessels.This study was in part supported by 17591823 and 16390495 from Japan Society for Promotion of Science.     

频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用

目的 评价频域光学相干断层扫描(optical coherence tomography,OCT)检查在光动力疗法(photodynamic therapy,PDT)治疗病理性近视所致的黄斑区脉络膜新生血管(choriodal neovascularization,CNV)中的临床应用价值.方法 对比分析21例26眼病理性近视患者PDT治疗前后频域OCT图像中黄斑中心凹层间厚度及外层高反射厚度,观察不同时期OCT的形态变化.结果 26眼CNV生长方式均属于Ⅱ型.PDT治疗后6个月18眼视网膜层间厚度恢复,视网膜下液吸收,CNV反光团逐渐缩小或纤维化,中心凹形态恢复.黄斑中心凹层间厚度治疗后1周(339.96±74.40)μm增加,治疗后1个月(267.78±33.39)μm开始下降,且差异均有统计学意义(均为P＜0.05).外层高反射厚度与术前(247.33±49.31)μm相比,从治疗后1个月(226.73±83.15)μm开始明显减少,但仅治疗后6个月(165.15±22.90)μm时差异有统计学意义(P=0.042).结论 频域OCT对病理性近视CNV行PDT治疗前后视网膜形态结构的连续观察具有重要意义,为临床治疗提供一种安全、无损伤的检测方法.     

Testing central retinal function with multifocal electroretinography before and after photodynamic therapy

BACKGROUND: Photodynamic therapy (PDT) is applied for certain forms of choroidal neovascular membrane (CNV). The aim of this study was to investigate the effect of PDT on central retinal function as assessed by multifocal electroretinography (ERG). METHODS: 24 patients (25 eyes) with CNV (>50% classic 12 eyes) or occult (9 eyes) in age related macular degeneration (AMD) and CNV with pathological myopia (4 eyes) were treated by PDT using Verteporfin((R)). Before and a median of 6 weeks after therapy, central retinal function was examined using multifocal ERG (RetiScan, 61 hexagons, first-order response). RESULTS: In the area of treatment,we found a tendency of the amplitude of the first positive deflection (P1) to decrease and of the implicit time to increase, but both effects were not statistically significant. These alterations were more pronounced in eyes with occult CNV and in myopia-related CNV. Amplitude reduction and implicit time prolongation could also be found in the areas represented by the multifocal ERG but not treated. There was no significant correlation between change in visual acuity after PDT and amplitude of the multifocal ERG. CONCLUSION: The effects of PDT on retinal function seem to be moderate as assessed by multifocal ERG. An inherent problem of this investigation was the recruitment of nontreated patients as controls. Future goals are investigations of patients with repeated PDT and of long-term alterations in multifocal ERG after PDT.     

Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia

Background To report long-term functional and morphological outcome of verteporfin photodynamic therapy (PDT) for classic extrafoveal choroidal neovascularisation (CNV) secondary to pathologic myopia.Methods This retrospective case series included three eyes of three consecutive patients with classic extrafoveal CNV secondary to pathologic myopia, who underwent PDT at a tertiary retinal referral centre. Change in visual acuity and fluorescein leakage was the main outcome criteria.Results The patients were followed up an average of 36 months (33–40 months). In all eyes increase of visual acuity (one eye 1 ETDRS line, two eyes 2 ETDRS line) and no fluorescein leakage of the CNV were seen.Conclusions PDT can achieve long-term improvement of the visual acuity and morphological stability in selected cases with classic extrafoveal CNV in pathologic myopia. Large scale randomised studies are warranted for assessment of the benefit of PDT in such eyes.Presented partly as a poster at the ARVO Meeting in Fort Lauderdale, May, 2003.     

Choroidal neovascularization in phakic eyes with anterior chamber intraocular lenses to correct high myopia

PURPOSE: To analyze the appearance, incidence, and characteristics of choroidal neovascularization (CNV) in patients with high myopia corrected by implantation of a phakic anterior chamber intraocular lens (PACL). SETTING: University Miguel Hernández, Instituto Oftalmológico de Alicante, Alicante, Spain. METHODS: The CNV observed in 294 consecutive eyes (181 patients) implanted with a PACL for the correction of high myopia (-7.0 to -38.0 diopters) was studied. The mean follow-up was 50.6 months +/- 32.8 (SD) (range 6 to 120 months). RESULTS: Choroidal neovascularization occurred in 5 eyes (1.70%); 3 eyes were in women, and 2 were in men. The interval between PACL implantation and CNV was 63.2 +/- 27.3 months (range 18 to 87 months). The CNV was subfoveal in 4 eyes and juxtafoveal in 1 case. The mean best spectacle-corrected visual acuity (BSCVA) after PACL implantation and before the appearance of CNV was 0.53 +/- 0.18 (range 0.4 [20/50] to 0.8 [20/25]); after CNV appeared, it was 0.26 +/- 0.18 (range 0.05 [20/400] to 0.5 [20/40]), a statistically significant difference (P =.001, paired Student t test). In 2 cases, the CNV was treated with photodynamic therapy (PDT); in the other 3 cases, PDT was rejected. The cumulative risk for CNV (Kaplan-Meier survival analysis) in highly myopic patients corrected by PACL implantation was 0.43% at 18 months and 5.4% at 87 months. CONCLUSIONS: Implantation of a PACL to correct high myopia was followed by a small incidence of CNV (cumulative risk of 5.4% at 87 months). The appearance of CNV was followed by a significant decrease in BSCVA.     

Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy

Background The purpose of this study was to examine the influence of treatment frequency on visual acuity of patients with PDT treatment for subfoveal predominantly classic CNV related to pathological myopia.Design Retrospective case series.Methods Thirty-seven patients with subfoveal predominantly classic CNV caused by pathologic myopia and treated with PDT were included. All patients received a full ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, fundus photography and fluorescein angiography, before first treatment and every 3 months thereafter. Photodynamic therapy was performed according to standard protocol. Main outcome measurements were visual acuity and treatment frequency.Results The number of treatments received was 3.35±1.83 (average: 1–7). In 12 eyes (32.43%); the BCVA was stable or increased during the entire follow-up period. In eight eyes (21.62%), the BCVA decreased and did not return to the baseline values. A transient loss of visual acuity (over 3–9 months) with subsequent improvement in visual function was found in 68% (17 eyes). A gain of three or more lines compared with lowest BCVA was found in 56% (14 eyes). The number of treatments did not correlate with baseline BCVA, greatest linear dimension of CNV at baseline or with the change of BCVA from baseline. In cases with transient worsening of BCVA, the recovery of visual acuity correlated significantly with the number of treatments (r=−0.522, P<0.05; Spearman rank correlation) received.Conclusion Visual acuity recovery correlates with the number of PDT re-treatments; in many cases, an improvement in visual function after temporary decrease of BCVA can be observed after re-treatment according to current treatment guidelines. The number of PDT treatments has no negative effect on the visual outcome in subfoveal CNVs caused by pathological myopia.